MEDEZE Targets 25% Growth in 2026, Accelerates Full-Scale Expansion into the Health Economy Partners with GPO to Establish a Joint Venture for Cell Culture Media Production, Upgrading from Biobank to Biopharma, While Advancing the JUMP+ Program to Strengthen Healthcare Capabilities and Sustainable Growth
Medeze Group Public Company Limited, or MEDEZE, has announced its strategic expansion into the Health Economy in a systematic and fully integrated manner under the vision “From Biobank to Biopharma.” The Company has set a growth target of 25% in 2026, supported by a joint venture with the Government Pharmaceutical Organization (GPO) to produce cell culture media domestically. This initiative marks a significant step in elevating MEDEZE’s business from a biobank platform to a biopharmaceutical player, while reinforcing long-term sustainable growth.
- The Company’s strategy is driven by three core pillars:
- the development of Advanced Therapy Medicinal Products (ATMPs)
- international market expansion through a franchise model, and
strategic investment in cell culture media manufacturing infrastructure to build long-term, sustainable growth.
Dr. Veerapol Khemarangsan,Chief Executive Officer of Medeze Group Public Company Limited, stated that 2026 will be a year of clear strategic transformation for MEDEZE, with the Company targeting a 25% growth rate. MEDEZE aims to build on its strengths in biobanking and advance toward leadership in the biopharmaceutical and advanced therapy industries, while simultaneously establishing a comprehensive health ecosystem to support the expansion of the Health Economy both domestically and across the region.
In terms of ATMP development, MEDEZE is focusing on innovation for degenerative diseases, with initial product development targeting knee osteoarthritis and skin degeneration. The Company plans to continuously register new products at an average rate of two disease indications per year, addressing growing demand for treatment, rehabilitation, and preventive healthcare amid an aging population.
At the same time, MEDEZE is expanding into international markets through a franchise model. The Company has already signed a business agreement in Mongolia and is preparing to commence operations in the Philippines in 2026. MEDEZE aims to expand into an additional country each year on average, building a structured regional Health Ecosystem.
From an infrastructure perspective, MEDEZE has entered into a strategic investment partnership with the Government Pharmaceutical Organization (GPO) and other partners to establish a joint venture focused on the domestic production of cell culture media. The initiative aims to reduce reliance on imported medical raw materials, strengthen the biomedical supply chain, and lay the foundation for Thailand—and Southeast Asia—to become a future manufacturing base for ATMPs.
MEDEZE also places strong emphasis on upgrading its operational standards to international levels. The Company plans to invest in robotics technology and laboratory automation systems, alongside upgrading all laboratories to comply with Good Manufacturing Practice (GMP) standards. These initiatives are designed to enhance efficiency, precision, and scalability, supporting long-term business expansion.
The joint venture, established between Medeze Group Public Company Limited, the Government Pharmaceutical Organization (GPO), and Cretan Associate Co., Ltd., will operate as a subsidiary of MEDEZE and is expected to commence commercial operations in the first quarter of 2026. The venture aims to reinforce Thailand’s biomedical supply chain, support the growth of ATMPs, biobanking, clinical research, and GMP-certified laboratories, and enhance the country’s competitiveness within the Health Economy sector.
In addition, MEDEZE is actively participating in the JUMP+ Program, an initiative supported by the Stock Exchange of Thailand designed to enhance the long-term value and competitiveness of listed companies. Participation in the program enables MEDEZE to systematically review and strengthen its business strategy, financial structure, corporate governance, and sustainable growth framework—ranging from organizational capability assessment and business model design to action plan execution and the integration of economic outcomes with long-term sustainability.
Looking ahead, MEDEZE plans to further expand its long-term business through continued ATMP innovation for treatment, rehabilitation, and preventive healthcare in degenerative diseases and aging societies. The Company will also expand its Health Ecosystem through collaboration with hospitals, clinics, research institutions, and domestic and international partners, while ensuring sustainable growth through strong corporate governance, risk management, and a structured ESG framework.
“MEDEZE does not focus solely on business growth, but also on creating shared value for the healthcare system, the economy, and society as a whole,” Dr. Weeraphol said. “Participation in the JUMP+ Program has enabled us to systematically review and enhance our business strategy—from organizational capability analysis and business model design to implementation planning and linking economic performance with long-term sustainability. This will serve as a key mechanism in driving investment in biomedical innovation and domestic manufacturing, positioning Thailand as a regional hub for the Health Economy in the future.”
IR Press Releases
